Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, and Guy BoivinComments to Author 
Author affiliations: McGill University Health Centre, Montréal, Québec, Canada (J. Papenburg); Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec City, Québec, Canada (J. Papenburg, J. Carbonneau, M.-È. Hamelin, S. Isabel, X. Bouhy, P. Déry, J. Corbeil, M.G. Bergeron, G. Boivin); Institut National de Santé Publique du Québec, Québec (N. Ohoumanne, G. De Serres); McMaster Children’s Hospital, Hamilton, Ontario, Canada (B.A. Paes)

Main Article

Table 2

Characteristics of 23 children in whom clinically significant respiratory syncytial virus respiratory tract infection developed while receiving palivizumab immunoprophylaxis, Canada, 2006–2010*

Location and patient ID Age, mo/ sex† GA at birth, wk + d Underlying
comorbidities No. doses PZB‡ Delay, d§ Clinical diagnoses H Multiplex PCR/DNA results Mutation
Québec City, Québec (2006–2010)
C0607-1023 9/F 32 + 4 Prematurity, LBW 3 21 Bronchiolitis No RSV-A;
enterovirus type A K272Q
H0607-064 24/M 38 + 3 Congenital myopathy 3 15 Pneumonia;
bronchospasm Yes RSV-B NF
H0607-132 12/M 38 + 5 Pulmonary artery stenosis 5 7 Bronchiolitis Yes RSV-A NF
H0708-199 4/M 30 + 4 Prematurity, VLBW 4 14 Bronchiolitis Yes RSV-B NF
H0809-037 11/F 27 + 5 Prematurity, ELBW 3 14 Bronchiolitis Yes RSV-A NF
C0809-1055 6/F 29 + 0 Prematurity, ELBW, triplet 4 27 Bronchiolitis No RSV-A N276S
C0809-1056 6/M 29 + 0 Prematurity, ELBW, triplet 4 27 Bronchiolitis No RSV-A N276S
C0809-1057 6/M 29 + 0 Prematurity, VLBW, triplet 4 27 Bronchiolitis No RSV-A N276S
H0910-004 4/F 39 + 5 Choanal hypoplasia 1 16 Apnea;
upper RTI Yes RSV-A N276S
H0910-140 6/M 25 + 5 Prematurity, ELBW 4 29 Bronchiolitis Yes RSV-B NF
H0910-144 13/F 26 + 5 Prematurity, VLBW 4 7 Pneumonia Yes RSV-A K272M, N276S
H0910-150 9/M 28 + 3 Prematurity, VLBW 4 12 Upper RTI;
acute otitis media Yes RSV-A;
adenovirus type C N276S
Montréal, Québec (2009–2010)
MCH0910-001 15/M 40 + 4 Total anomalous pulmonary venous return 3 26 Pneumonia Yes RSV¶ N276S
MCH0910-002 6/F 39 + 0 Pulmonary valve stenosis, right aortic arch 2 7 Bronchiolitis Yes RSV¶ N276S
MCH0910-003 5/M 39 + 6 Cystic fibrosis 3 24 Bronchiolitis No RSV¶ N276S
MCH0910-004 7/M 36 + 2 Prematurity, BPD hypotonia 4 6 Bronchiolitis Yes RSV¶ N276S
MCH0910-005 15/M 40 + 4 Neuromuscular disorder, recurrent aspirations 4 13 Upper RTI;
acute otitis media No RSV¶ N276S
MCH0910-006 2/M 34 + 6 Prematurity, LBW 1 14 Bronchiolitis Yes RSV¶ N276S
MCH0910-007 19/F 25 + 0 Prematurity, ELBW, BPD 3 19 Bronchiolitis, bronchospasm Yes RSV¶ N276S
MCH0910-008 2/F 38 + 1 Neuromuscular disorder, ventricular septal defect 2 12 Bronchiolitis Yes RSV¶ N276S
Hamilton, Ontario (2009–2010)
MAC0910-001 1/F 34 + 5 Prematurity, LBW 2 3 Bronchiolitis Yes RSV¶ N276S
MAC0910-002 6/F 34 + 3 Prematurity, LBW, twin 1 25 Bronchiolitis Yes RSV¶ N276S
MAC0910-003 6/F 34 + 3 Prematurity,
VLBW, IUGR, twin 1 27 Bronchiolitis Yes RSV¶ N276S

*Patient identification (ID) nomenclature: hospitalized (H) or clinic (C) prospective study participant, Montréal Children’s Hospital (MCH) or McMaster Children’s Hospital (MAC) patient. GA, gestational age; PZB, palivizumab; multiplex PCR/DNA, hybridization assay; mutation, mutation in respiratory syncytial virus fusion protein PZB binding site (residues 262–276); RSV, respiratory syncytial virus; LBW, low birthweight (1,500–2,500 g); NF, no mutation found in PZB binding site; VLBW, very low birthweight (1,000–1,499 g); ELBW, extremely low birthweight (<1,000 g); RTI, respiratory tract infection; BPD, bronchopulmonary dysplasia; IUGR, intrauterine growth restriction.
†Median patient age 6.0 mo (range 1–24 mo).
‡Mean ± SD no. palivizumab doses received that winter: 3.0 ± 1.2 doses.
§Median interval between last palivizumab dose and symptom onset: 15.0 d (range 3–27 d).
¶Retrospectively identified participants from Montréal Children’s Hospital or McMaster Children’s Hospital were RSV-positive by direct immunofluorescence assay (Chemicon International, Temecula, CA, USA) and were not tested by the multiplex PCR/DNA hybridization assay (14).

Main Article

  1. Nair  H, Nokes  DJ, Gessner  BD, Dherani  M, Madhi  SA, Singleton  RJ, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:154555. DOIPubMedGoogle Scholar
  2. Welliver  RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143:S1127. DOIPubMedGoogle Scholar
  3. Collins  PL, Crowe  JE. Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM, editors. Field’s virology.,5th ed. New York: Lippincott Williams and Wilkins; 2007. p. 1601–46.
  4. Crowe  JE, Firestone  CY, Crim  R, Beeler  JA, Coelingh  KL, Barbas  CF, Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus–neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology. 1998;252:3735. DOIPubMedGoogle Scholar
  5. Huang  K, Incognito  L, Cheng  X, Ulbrandt  ND, Wu  H. Respiratory syncytial virus–neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010;84:813240. DOIPubMedGoogle Scholar
  6. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements–modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694701. DOIPubMedGoogle Scholar
  7. Zhao  X, Chen  FP, Megaw  AG, Sullender  WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis. 2004;190:19416. DOIPubMedGoogle Scholar
  8. Adams  O, Bonzel  L, Kovacevic  A, Mayatepek  E, Hoehn  T, Vogel  M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis. 2010;51:1858. DOIPubMedGoogle Scholar
  9. Zhu  Q, McAuliffe  JM, Patel  NK, Palmer-Hill  FJ, Yang  CF, Liang  B, Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis. 2011;203:67482. DOIPubMedGoogle Scholar
  10. Kim  YK, Choi  EH, Lee  HJ. Genetic variability of the fusion protein and circulation patterns of genotypes of the respiratory syncytial virus. J Med Virol. 2007;79:8208. DOIPubMedGoogle Scholar
  11. Zheng  H, Storch  GA, Zang  C, Peret  TC, Park  CS, Anderson  LJ. Genetic variability in envelope-associated protein genes of closely related group A strains of respiratory syncytial virus. Virus Res. 1999;59:8999. DOIPubMedGoogle Scholar
  12. Gilca  R, De Serres  G, Tremblay  M, Vachon  ML, Leblanc  E, Bergeron  MG, Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193:548. DOIPubMedGoogle Scholar
  13. Peret  TC, Hall  CB, Hammond  GW, Piedra  PA, Storch  GA, Sullender  WM, Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181:18916. DOIPubMedGoogle Scholar
  14. Raymond  F, Carbonneau  J, Boucher  N, Robitaille  L, Boisvert  S, Wu  WK, Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. J Clin Microbiol. 2009;47:74350. DOIPubMedGoogle Scholar
  15. Boivin  G, Caouette  G, Frenette  L, Carbonneau  J, Ouakki  M, De Serres  G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol. 2008;42:527. DOIPubMedGoogle Scholar

Main Article

Page created: December 20, 2011
Page updated: December 20, 2011
Page reviewed: December 20, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.